CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...